Emergent BioSolutions (EBS) Net Cash Flow Growth (1y) (2011 - 2026)
Emergent BioSolutions (EBS) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.15 Bn | 20.99 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | -1,020.00% |
| 10 | Emergent BioSolutions | 385.88 Mn | 224.38 Mn | 84.10 Mn | -199.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -199.37% |
| Dec 31, 2025 | 21.06% |
| Sep 30, 2025 | -125.29% |
| Jun 30, 2025 | 1,565.00% |
| Mar 31, 2025 | 246.48% |
| Dec 31, 2024 | -300.00% |
| Sep 30, 2024 | 4,594.74% |
| Jun 30, 2024 | 97.67% |
| Mar 31, 2024 | 84.40% |
| Dec 31, 2023 | -93.66% |
| Sep 30, 2023 | 98.37% |
| Jun 30, 2023 | -338.27% |
| Mar 31, 2023 | -49.71% |
| Dec 31, 2022 | 132.44% |
| Sep 30, 2022 | -167.36% |
| Jun 30, 2022 | 21.99% |
| Mar 31, 2022 | -91.26% |
| Dec 31, 2021 | -16.68% |
| Sep 30, 2021 | -129.67% |
| Jun 30, 2021 | -214.86% |